Literature DB >> 1679252

When symptoms persist: choosing among alternative somatic treatments for schizophrenia.

G W Christison1, D G Kirch, R J Wyatt.   

Abstract

Many patients with schizophrenia continue to have significant disabling symptoms despite adequate trials of different types and doses of traditional neuroleptics. Clinicians treating these neuroleptic-resistant patients must look to other treatments in the hope of providing some relief. The literature on many of the alternative treatments is too scanty for firm conclusions. We offer criteria for deciding which treatments may warrant consideration. We review the evidence for the eight treatments we found to meet these criteria and discuss clinical points salient to their use in this population. Although not always conclusive, the data do offer clues for treatment guidelines and an approach to choosing among the available treatments is suggested.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679252     DOI: 10.1093/schbul/17.2.217

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  27 in total

1.  Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia--an open label study.

Authors:  K H Kho; B A Blansjaar; S de Vries; D Babuskova; A H Zwinderman; D H Linszen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

2.  Rustom Jal Vakil: his contributions to cardiology.

Authors:  Sumit Isharwal; Shubham Gupta
Journal:  Tex Heart Inst J       Date:  2006

Review 3.  Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential.

Authors:  J M Kane
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

4.  Antipsychotic combinations for schizophrenia.

Authors:  Nicola Maayan; Karla Soares-Weiser; Jun Xia; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2011

5.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

6.  Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial.

Authors:  W H Wilson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 7.  Drug treatment of resistant schizophrenia. Limitations and recommendations.

Authors:  A E Farmer; A Blewett
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

8.  Concept and Management of Treatment Resistant Schizophrenia (TRS).

Authors:  Nitesh Painuly; Nitin Gupta; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

Review 9.  Benzodiazepines for schizophrenia.

Authors:  Markus Dold; Chunbo Li; Magdolna Tardy; Vesal Khorsand; Donna Gillies; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

Review 10.  Lithium. Current status in psychiatric disorders.

Authors:  M Peet; J P Pratt
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.